World's Best Scientists 2026 revealed!
Jitka Fucikova

Jitka Fucikova

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Immunology 50 4214 3892 4 4 141 11211

Jitka Fucikova publications per year

The chart shows the history of publications by Jitka Fucikova between 2009 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Jitka Fucikova published across 17 years, from 2009 to 2025, averaging 9 papers a year. Output peaked at 37 publications in 2023. 18 of the 153 publications appeared in the last two years.

No. of publications
10 20 30
Bar chart. Horizontal axis: year, 2009 to 2025. Vertical axis: number of publications, 0 to 37. Peak 37 publications in 2023. 2009: 2 publications 2010: 0 publications 2011: 2 publications 2012: 2 publications 2013: 6 publications 2014: 12 publications 2015: 11 publications 2016: 9 publications 2017: 6 publications 2018: 11 publications 2019: 6 publications 2020: 17 publications 2021: 8 publications 2022: 6 publications 2023: 37 publications 2024: 6 publications 2025: 12 publications
2009 2025

153 publications in total across all disciplines

View publications per year as a table
Jitka Fucikova: publications per year, 2009 to 2025
Year Publications
2009 2
2010 0
2011 2
2012 2
2013 6
2014 12
2015 11
2016 9
2017 6
2018 11
2019 6
2020 17
2021 8
2022 6
2023 37
2024 6
2025 12
Total 153
Download as CSV

Jitka Fucikova publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Jitka Fucikova sits on this spectrum.

No. of scientists
50 100 150
Bar chart with 76 bars. Horizontal axis: publications, 62–71 to 807+. Vertical axis: number of scientists, 0 to 189. Most scientists, 189, have 152–161 publications. The last bar groups every scientist with 807 publications or more. The highlighted bar, 132–141 publications, is where this scientist sits. 62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientist 807+ publications: 100 scientists
62–71 publications 807+

This scientist: 141 publications — 13th percentile

13% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

View publications distribution as a table
Number of Immunology scientists by publication count, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
Publications Scientists This scientist
62–71 9
72–81 23
82–91 40
92–101 72
102–111 86
112–121 108
122–131 150
132–141 160 141
142–151 159
152–161 189
162–171 166
172–181 181
182–191 188
192–201 187
202–211 178
212–221 158
222–231 168
232–241 159
242–251 160
252–261 148
262–271 116
272–281 125
282–291 115
292–301 111
302–311 95
312–321 97
322–331 97
332–341 99
342–351 96
352–361 69
362–371 76
372–381 71
382–391 71
392–401 62
402–411 54
412–421 41
422–431 63
432–441 53
442–451 31
452–461 42
462–471 40
472–481 29
482–491 34
492–501 30
502–511 23
512–521 41
522–531 29
532–541 28
542–551 16
552–561 18
562–571 18
572–581 17
582–591 17
592–601 17
602–611 19
612–621 13
622–631 12
632–641 11
642–651 16
652–661 9
662–671 5
672–681 13
682–691 12
692–701 6
702–711 6
712–721 9
722–731 9
732–741 6
742–751 11
752–761 10
762–771 7
772–781 12
782–791 7
792–801 5
802–806 1
807+ 100
Download as CSV

Jitka Fucikova D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Jitka Fucikova sits on this spectrum.

No. of scientists
50 100 150 200
Bar chart with 60 bars. Horizontal axis: D-Index, 40–41 to 157+. Vertical axis: number of scientists, 0 to 201. Most scientists, 201, have 58–59 D-Index. The last bar groups every scientist with 157 D-Index or more. The highlighted bar, 50–51 D-Index, is where this scientist sits. 40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40–41 D-Index 157+

This scientist: 50 D-Index — 15th percentile

15% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

View D-Index distribution as a table
Number of Immunology scientists by D-index, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
D-Index Scientists This scientist
40–41 28
42–43 91
44–45 157
46–47 192
48–49 175
50–51 188 50
52–53 177
54–55 155
56–57 194
58–59 201
60–61 197
62–63 201
64–65 173
66–67 167
68–69 172
70–71 199
72–73 184
74–75 133
76–77 163
78–79 127
80–81 121
82–83 125
84–85 121
86–87 102
88–89 96
90–91 75
92–93 72
94–95 74
96–97 66
98–99 68
100–101 49
102–103 60
104–105 54
106–107 36
108–109 23
110–111 52
112–113 41
114–115 34
116–117 25
118–119 28
120–121 11
122–123 20
124–125 27
126–127 19
128–129 20
130–131 16
132–133 17
134–135 14
136–137 15
138–139 9
140–141 11
142–143 9
144–145 9
146–147 7
148–149 7
150–151 7
152–153 5
154–155 8
156 6
157+ 96
Download as CSV

Overview

Jitka Fucikova is affiliated with Charles University in the Czech Republic and has contributed extensively to the fields of medicine, immunology, and microbiology. Their research primarily focuses on immunology, oncology, and molecular biology, with specific interest in cancer immunotherapy and immune system responses.

Their scholarly output includes 58 publications in medicine, with 41 of these focusing specifically on immunology and microbiology. Within these domains, the subfields of immunology, oncology, reproductive medicine, molecular biology, and genetics are notably represented in their work.

The main research topics addressed by Jitka Fucikova encompass:

  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • Immune Cell Function and Interaction
  • Ovarian Cancer Diagnosis and Treatment
  • Immune Cells in Cancer
  • CAR-T Cell Therapy Research
  • Phagocytosis and Immune Regulation

Frequent coauthors in their collaborative research include Radek Špíšek, Lorenzo Galluzzi, Michal Hensler, Lenka Kašíková, and Lukáš Rob.

Jitka Fucikova's work has been published predominantly in journals such as OncoImmunology, Cancer Immunology Research, Journal for ImmunoTherapy of Cancer, Nature Communications, and Cell Death and Disease.

Notable papers authored or coauthored by Jitka Fucikova include:

  • "Consensus guidelines for the definition, detection and interpretation of immunogenic cell death," 2020, Journal for ImmunoTherapy of Cancer
  • "Detection of immunogenic cell death and its relevance for cancer therapy," 2020, Cell Death and Disease
  • "Calreticulin and cancer," 2020, Cell Research
  • "Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology," 2020, OncoImmunology
  • "Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer," 2020, Nature Communications

Best Publications

  • Detection of immunogenic cell death and its relevance for cancer therapy

    Jitka Fucikova;Oliver Kepp;Lenka Kasikova;Giulia Petroni

  • Consensus guidelines for the detection of immunogenic cell death

    Oliver Kepp;Laura Senovilla;Ilio Vitale;Erika Vacchelli

  • Classification of current anticancer immunotherapies

    Lorenzo Galluzzi;Erika Vacchelli;José Manuel Bravo-San Pedro;Aitziber Buqué

  • Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response

    Jitka Fucikova;Petra Kralikova;Anna Fialova;Tomas Brtnicky

  • Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death

    Abhishek D. Garg;Lorenzo Galluzzi;Lionel Apetoh;Lionel Apetoh;Thais Baert

  • Combinatorial Strategies for the Induction of Immunogenic Cell Death

    Lucillia Bezu;Ligia C. Gomes-de-Silva;Heleen Dewitte;Karine Breckpot

  • Calreticulin and cancer

    Jitka Fucikova;Radek Spisek;Guido Kroemer;Lorenzo Galluzzi

  • Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.

    Jonathan Pol;Erika Vacchelli;Fernando Aranda;Francesca Castoldi

  • Trial watch: Dendritic cell-based interventions for cancer therapy.

    Erika Vacchelli;Ilio Vitale;Alexander Eggermont;Wolf Hervé Fridman

  • Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma

    Simona Partlová;Jan Bouček;Kamila Kloudová;Eva Lukešová

  • Trial Watch: Toll-like receptor agonists in cancer immunotherapy

    Melody Smith;Elena García-Martínez;Michael R. Pitter;Jitka Fucikova

  • Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology.

    Isaure Vanmeerbeek;Jenny Sprooten;Dirk De Ruysscher;Sabine Tejpar

  • Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy

    Irena Adkins;Jitka Fucikova;Abhishek D Garg;Patrizia Agostinis

  • Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis.

    Jitka Fucikova;Etienne Becht;Etienne Becht;Etienne Becht;Kristina Iribarren;Kristina Iribarren;Kristina Iribarren;Jeremy Goc;Jeremy Goc;Jeremy Goc

  • High hydrostatic pressure induces immunogenic cell death in human tumor cells.

    Jitka Fucikova;Irena Moserova;Iva Truxova;Ivana Hermanova

  • Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients

    Iva Truxova;Lenka Kasikova;Michal Hensler;Petr Skapa

  • Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications.

    Jitka Fucikova;Lenka Palova-Jelinkova;Jirina Bartunkova;Radek Spisek

  • Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer

    Jitka Fucikova;Irena Moserova;Linda Urbanova;Lucillia Bezu

  • Trial watch: Dendritic cell (DC)-based immunotherapy for cancer

    Unknown

  • Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer

    Michal Podrazil;Rudolf Horvath;Etienne Becht;Daniela Rozkova

  • Trial watch: Peptide-based vaccines in anticancer therapy.

    Lucillia Bezu;Oliver Kepp;Giulia Cerrato;Jonathan Pol

Frequent Co-Authors

Radek Spisek
Radek Spisek Sotio (Czechia)
Lorenzo Galluzzi
Lorenzo Galluzzi Cornell University
Guido Kroemer
Guido Kroemer Université Paris Cité
Laurence Zitvogel
Laurence Zitvogel University of Paris-Saclay
Isabelle Cremer
Isabelle Cremer Sorbonne University
Oliver Kepp
Oliver Kepp Institut Gustave Roussy
Catherine Sautès-Fridman
Catherine Sautès-Fridman Université Paris Cité
Eric Tartour
Eric Tartour Université Paris Cité
Takahiro Yamazaki
Takahiro Yamazaki Cornell University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in careers linked to Immunology, pursuing advanced nursing degrees can be a viable pathway. Many students explore options such as psychiatric nursing, a specialty closely connected to mental health and immunological research. Finding the best pmhnp programs online can help ensure strong clinical training and improved employment prospects after graduation.

Cost is also a crucial consideration. It’s important to balance educational quality with affordability, and exploring the affordable pmhnp programs can provide options for students on a budget while still gaining comprehensive knowledge and skills.

Understanding the financial outlook of these degrees is equally essential. According to recent data, salaries for Doctor of Nursing Practice (DNP) holders vary significantly by location. Learn more about how much does a dnp make to gauge potential earnings and career sustainability in different states.

Career advancement often involves additional certifications. For example, nurses can transition from Family Nurse Practitioner (FNP) roles to more specialized fields, such as acute care. Guidance on this transition can be found by exploring resources on fnp to acute care certification, which may open new doors within healthcare related to immunological conditions.

Best Scientists Citing Jitka Fucikova

Trending Scientists

Recently Published Articles